MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461...
(Source: MyoKardia Inc) MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied Company Plans...
View ArticleInotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose...
(Source: Inotek Pharmaceuticals Corporation) -Data Expected in 2017- LEXINGTON, Mass--(BUSINESS WIRE)--Jul. 12, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage...
View ArticleAnthera Provides Clinical Program Updates for Blisibimod and Sollpura®...
(Source: Anthera Pharmaceuticals Inc) Positive trends from BRIGHT-SC proof-of-concept study - study to continue SOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016...
View ArticleNew Janssen Phase 3 Data In Patients With Moderately To Severely Active...
(Source: Johnson & Johnson) 6b013b02-b92b-48fe-a032-f436d13689f0.pdf June 8, 2016 New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab...
View ArticleProthena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating...
(Source: Prothena Corporation plc) New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%,...
View ArticleGlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of...
(Source: GlycoMimetics Inc) ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the...
View ArticleUltragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant...
(Source: Ultragenyx Pharmaceutical Inc) Study meets primary endpoint of reduction in urinary GAG excretion and provides evidence of clinical improvement Company to host conference call today at 5pm ET...
View ArticleAnthera Provides Clinical Program Updates for Blisibimod and Sollpura®
Positive trends from BRIGHT-SC proof-of-concept study – study to continue SOLUTION study with Sollpura completed patient screening ahead of schedule – data in 2016 First patients screened in Phase 3...
View ArticleMediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b...
(Source: MediciNova Inc) LA JOLLA, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the...
View ArticleNew Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with...
New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress Alexion Pharmaceuticals, Inc....
View ArticleNew Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with...
(Source: Alexion Pharmaceuticals Inc) NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers presented new results from the REGAIN study, a...
View ArticleTwo Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive...
(Source: Pfizer Inc) Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a...
View ArticleInotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose...
Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost -Data Expected in 2017- Inotek Pharmaceuticals...
View ArticleMediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b...
LA JOLLA, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
View ArticleCara Therapeutics Initiates Adaptive Phase 2/3 Trial of I.V. CR845 for...
(Source: CARA Therapeutics Inc) STAMFORD, Conn., June 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical...
View ArticleCardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors: The...
(Source: American College of Cardiology Foundation) For close to 100 years since the introduction of insulin for clinical use in 1922, no medication designed to treat hyperglycemia associated with...
View ArticleBionomics to Trial Drug Against Post-Traumatic Stress Disorder (Bionomics...
(Source: Bionomics Limited) 30cbb2b4-6a94-407a-b184-196dd778cf00.pdf ABN 53 075 582 740 ASX ANNOUNCEMENT 30 June 2016 BIONOMICS TO TRIAL DRUG AGAINST POST-TRAUMATIC STRESS DISORDER Trial to examine...
View ArticleIdalopirdine granted Fast Track Designation by U.S. Food and Drug...
(Source: H Lundbeck A/S) Designation provides the opportunity for more frequent interactions with FDA during clinical development and potential eligibility for priority review Valby, 2016-07-07 15:00...
View ArticleSecondary Venous Thromboembolism Prevention in Patients with a Malignancy...
(Source: American College of Cardiology Foundation) Among the known risk factors for venous thromboembolism (VTE), cancer remains one of the most potent. In a 15-year population study, patients with an...
View ArticlevTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral...
(Source: VTV Therapeutics Inc) Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation - three of the principal causes of neuronal...
View Article